Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes

被引：0
作者：
Vaia Lambadiari
George Pavlidis
Foteini Kousathana
Maria Varoudi
Dimitrios Vlastos
Eirini Maratou
Dimitrios Georgiou
Ioanna Andreadou
John Parissis
Helen Triantafyllidi
John Lekakis
Efstathios Iliodromitis
George Dimitriadis
Ignatios Ikonomidis
机构：
[1] Attikon University Hospital,2nd Department of Internal Medicine, Research Unit and Diabetes Center
[2] National and Kapodistrian University of Athens,2nd Cardiology Department
[3] Medical School,Department of Pharmaceutical Chemistry, School of Pharmacy
[4] Attikon Hospital,undefined
[5] National and Kapodistrian University of Athens,undefined
[6] Medical School,undefined
[7] Hellenic National Center for the Prevention of Diabetes and Its Complications HNDC,undefined
[8] National and Kapodistrian University of Athens,undefined
来源：
Cardiovascular Diabetology | / 17卷
关键词：
Arterial stiffness; Augmentation index; Glp-1 analogue; Liraglutide; Metformin; Left ventricular function; Oxidative stress;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 39 条
  • [31] Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of theLEADERandSUSTAIN6 trials
    Verma, Subodh
    McGuire, Darren K.
    Bain, Stephen C.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Mazer, C. David
    Monk Fries, Tea
    Pratley, Richard E.
    Rasmussen, Soren
    Vrazic, Hrvoje
    Zinman, Bernard
    Buse, John B.
    DIABETES OBESITY & METABOLISM, 2020, 22 (12) : 2487 - 2492
  • [32] A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus
    Owens, David R.
    Monnier, Louis
    Hanefeld, Markolf
    DIABETES OBESITY & METABOLISM, 2017, 19 (12) : 1645 - 1654
  • [33] Glucagon-like peptide-1 loaded phospholipid micelles for the treatment of type 2 diabetes: improved pharmacokinetic behaviours and prolonged glucose-lowering effects
    Cui, Xu
    Meng, Qinghua
    Chu, Yingying
    Gu, Xiaoke
    Tang, Yan
    Zhou, Feng
    Fei, Yingying
    Fu, Junjie
    Han, Jing
    RSC ADVANCES, 2016, 6 (97): : 94408 - 94416
  • [34] Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
    Ida, Satoshi
    Kaneko, Ryutaro
    Imataka, Kanako
    Okubo, Kaoru
    Shirakura, Yoshitaka
    Azuma, Kentaro
    Fujiwara, Ryoko
    Takahashi, Hiroka
    Murata, Kazuya
    HEART FAILURE REVIEWS, 2021, 26 (05) : 1151 - 1158
  • [35] Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
    Lambadiari, Vaia
    Thymis, John
    Kouretas, Dimitris
    Skaperda, Zoi
    Tekos, Fotios
    Kousathana, Foteini
    Kountouri, Aikaterini
    Balampanis, Konstantinos
    Parissis, John
    Andreadou, Ioanna
    Tsoumani, Maria
    Chania, Christina
    Katogiannis, Konstantinos
    Dimitriadis, George
    Bamias, Aristotelis
    Ikonomidis, Ignatios
    ANTIOXIDANTS, 2021, 10 (09)
  • [36] The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
    Umpierrez, G. E.
    Blevins, T.
    Rosenstock, J.
    Cheng, C.
    Anderson, J. H.
    Bastyr, E. J., III
    DIABETES OBESITY & METABOLISM, 2011, 13 (05) : 418 - 425
  • [37] Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
    Preman Kumarathurai
    Christian Anholm
    Olav W. Nielsen
    Ole P. Kristiansen
    Jens Mølvig
    Sten Madsbad
    Steen B. Haugaard
    Ahmad Sajadieh
    Cardiovascular Diabetology, 15
  • [38] Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
    Kumarathurai, Preman
    Anholm, Christian
    Nielsen, Olav W.
    Kristiansen, Ole P.
    Molvig, Jens
    Madsbad, Sten
    Haugaard, Steen B.
    Sajadieh, Ahmad
    CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [39] Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
    Odawara, M.
    Miyagawa, J.
    Iwamoto, N.
    Takita, Y.
    Imaoka, T.
    Takamura, T.
    DIABETES OBESITY & METABOLISM, 2016, 18 (03) : 249 - 257
1234